Process analytics 4.0: A paradigm shift in rapid analytics for biologics development
Abstract
Analytical testing of product quality attributes and process parameters during the biologics development (Process analytics) has been challenging due to the rapid growth of biomolecules with complex modalities to support unmet therapeutic needs. Thus, the expansion of the process analytics tool box for rapid analytics with the deployment of cutting-edge technologies and cyber-physical systems is a necessity. We introduce the term, Process Analytics 4.0; which entails not only technology aspects such as process analytical technology (PAT), assay automation, and high-throughput analytics, but also cyber-physical systems that enable data management, visualization, augmented reality, and internet of things (IoT) infrastructure for real time analytics in process development environment. This review is exclusively focused on dissecting high-level features of PAT, automation, and data management with some insights into the business aspects of implementing during process analytical testing in biologics process development. Significant technological and business advantages can be gained with the implementation of digitalization, automation, and real time testing. A systematic development and employment of PAT in process development workflows enable real time analytics for better process understanding, agility, and sustainability. Robotics and liquid handling workstations allow rapid assay and sample preparation automation to facilitate high-throughput testing of attributes and molecul…
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Cites
Biopharmaceutical benchmarks 2018
Walsh, G. (2018) · Nature Biotechnology · doi:10.1038/nbt.4305 · Cited by 978 · cited 1× · see citing works
“Biotherapeutic modalities evolve rapidly to deliver unmet patient needs, which require the development and amendment of typical analytical assays for CQAs and CPPs.(80) Unlike manual assays, it would be challenging to simply amend or re-develop automated or PAT type real time analytical assays for specialized biologic…”
MethodWasalathanthri, D. P., Rehmann, M. S., Song, Y., Gu, Y., Mi, L., Shao, C., Chemmalil, L., Lee, J., Ghose, S., Borys, M. C., et al. (2020) · Biotechnology and Bioengineering · doi:10.1002/bit.27461 · Cited by 177 · see citing works
Self-citationWhelan, J., Craven, S., & Glennon, B. (2012) · Biotechnology Progress · doi:10.1002/btpr.1590 · Cited by 159 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Current PAT Landscape in the Downstream Processing of Biopharmaceuticals
Sathiyapriyan, P., Mukherjee, S., Vogel, T., Essen, L., Boerema, D., Vey, M., & Kalina, U. (2025) · Analytical Science Advances · doi:10.1002/ansa.70013 · Cited by 45 · see citing works
Non-invasive real-time monitoring of cell concentration and viability using Doppler ultrasound.
Akbari, S., Anderson, P., Zang, H., Ganjian, A., Balke, R., Kwon, T., & Pollard, D. (2022) · SLAS technology · doi:10.1016/j.slast.2022.09.003 · Cited by 11 · see citing works
- Authors
- Wasalathanthri, D. P., Shah, R., Ding, J., Leone, A., & Li, Z. J.
- Affiliations
- Bristol-Myers Squibb (United States) (US)
- Corresponding author
- Wasalathanthri, Dhanuka P.
- Venue
- Biotechnology Progress
- Publisher
- Wiley
- Published
- 2021-05-31
- Volume
- 37
- Issue
- 4
- Pages
- e3177-e3177
- ISSN
- 1520-6033 (ISSN-L)
- 8756-7938
- OpenAlex
- W3165727984
- Cited by
- 17
- References
- 3
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 4 · 2023: 2 · 2022: 4
- FWCI
- 0.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Biotechnology Progress (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
- Keywords
- process analytical technology, biopharmaceutical process development, real-time analytics, assay automation, cyber-physical systems, data management, Internet of Things, augmented reality, digitalization, automated liquid handling, product quality attributes, process parameters
- MeSH terms
- Automation, Biological Products, Workflow
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review